{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:56:24Z","timestamp":1785538584298,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1124\/dmd.122.001024","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T19:50:11Z","timestamp":1670442611000},"page":"306-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Contribution of UGT Enzymes to Human Drug Metabolism Stereoselectivity: A Case Study of Medetomidine, RO5263397, Propranolol, and Testosterone"],"prefix":"10.1016","volume":"51","author":[{"given":"Nicol\u00f2","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NaHong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-3559","authenticated-orcid":false,"given":"Stephen","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.001024_bib1","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/nrd3657-c1","article-title":"The predicated demise of racemic new molecular entities is an exaggeration","volume":"11","author":"Agranat","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.001024_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1124\/dmd.121.000813","article-title":"Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5\u2032-Diphosphate Glucuronosyltransferase","volume":"50","author":"Ahmed","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2125.1984.tb02462.x","article-title":"Stereoselective binding of propranolol enantiomers to human alpha 1-acid glycoprotein and human plasma","volume":"18","author":"Albani","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001024_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40262-018-0681-2","article-title":"The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling","volume":"58","author":"Bad\u00e9e","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1124\/dmd.122.001024_bib5","first-page":"S42","article-title":"Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes","volume":"59","author":"Bad\u00e9e","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001024_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/dmd.118.084301","article-title":"Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry","volume":"47","author":"Bad\u00e9e","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","article-title":"Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver","volume":"8","author":"Barter","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.001024_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/dmd.115.069096","article-title":"Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions\u2014an industry perspective","volume":"44","author":"Bohnert","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jpba.2017.07.008","article-title":"The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds","volume":"147","author":"Calcaterra","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.122.001024_bib10","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.3390\/molecules26113113","article-title":"Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods","volume":"26","author":"Coelho","year":"2021","journal-title":"Molecules"},{"key":"10.1124\/dmd.122.001024_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2165\/00003088-199528020-00002","article-title":"Clinical pharmacokinetics of flurbiprofen and its enantiomers","volume":"28","author":"Davies","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.001024_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1208\/s12248-020-00513-5","article-title":"Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine","volume":"22","author":"Docci","year":"2020","journal-title":"AAPS J"},{"key":"10.1124\/dmd.122.001024_bib13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/jpet.114.220194","article-title":"A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure","volume":"352","author":"Fowler","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001024_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000165100","article-title":"Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7","volume":"82","author":"Hanioka","year":"2008","journal-title":"Pharmacology"},{"key":"10.1124\/dmd.122.001024_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/dmd.113.054718","article-title":"UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues","volume":"42","author":"Jones","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib16","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1124\/dmd.108.021709","article-title":"Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes","volume":"36","author":"Kaivosaari","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1208\/s12248-016-0019-7","article-title":"Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling","volume":"19","author":"Kratochwil","year":"2017","journal-title":"AAPS J"},{"key":"10.1124\/dmd.122.001024_bib18","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1124\/dmd.111.041418","article-title":"Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9","volume":"39","author":"Manevski","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054767","article-title":"Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent","volume":"8","author":"Manevski","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.122.001024_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/dmd.119.089482","article-title":"Use of Phenotypically Poor Metabolizer Individual Donor Human Liver Microsomes To Identify Selective Substrates of UGT2B10","volume":"48","author":"Milani","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib21","first-page":"829","article-title":"In vitro glucuronidation of propofol in microsomal fractions from human liver, intestine and kidney: tissue distribution and physiological role of UGT1A9","volume":"69","author":"Mukai","year":"2014","journal-title":"Pharmazie"},{"key":"10.1124\/dmd.122.001024_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/clpt.1984.107","article-title":"Stereoselective clearance and distribution of intravenous propranolol","volume":"35","author":"Olanoff","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001024_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/dmd.115.068213","article-title":"Human UDP-glucuronosyltransferase (UGT) 2B10: validation of cotinine as a selective probe substrate, inhibition by UGT enzyme-selective inhibitors and antidepressant and antipsychotic drugs, and structural determinants of enzyme inhibition","volume":"44","author":"Pattanawongsa","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1124\/dmd.107.019885","article-title":"The \u201calbumin effect\u201d and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jps.2600710623","article-title":"Stereoselective disposition and glucuronidation of propranolol in humans","volume":"71","author":"Silber","year":"1982","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.122.001024_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/dmd.108.024844","article-title":"UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly","volume":"37","author":"Sten","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib27","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1124\/dmd.106.010371","article-title":"Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10","volume":"34","author":"Sten","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib28","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/dmd.121.000474","article-title":"Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes","volume":"49","author":"Takahashi","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib29","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.1983.240","article-title":"Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin","volume":"34","author":"Walle","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.001024_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/dmd.111.043117","article-title":"Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib32","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.bcp.2011.08.004","article-title":"Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen","volume":"82","author":"Wang","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001024_bib33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001024_bib34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/chir.20765","article-title":"Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9","volume":"22","author":"Yu","year":"2010","journal-title":"Chirality"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624009486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.001024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:59:26Z","timestamp":1739955566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624009486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0090955624009486"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.001024","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of UGT Enzymes to Human Drug Metabolism Stereoselectivity: A Case Study of Medetomidine, RO5263397, Propranolol, and Testosterone","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.001024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}